One of the major limitations of cancer gene therapy using recombinant human adenovirus (Ad) is rapid Ad inactivation from systemic delivery. To eliminate this, biotin-coated ultrasound contrast agents, or microbubbles (MBs), were streptavidin-coupled with biotinylated antibodies to three distinct tumor vasculature-associated receptors (a V b 3 integrin, P-selectin and vascular endothelial growth factor receptor-2) for systemic targeting of a previously generated vector Ad5/3-Id1-SEAP-Id1-mCherry. This cancer-specific, dual-reporter vector was loaded in the targeted MBs and confirmed by confocal microscopy. MB loading capacity was estimated by functional assays as 4.72±0.2 plaque forming unit (PFU) per MB. Non-loaded (free) Ad particles were effectively inactivated by treatment with human complement. The Ad-loaded, targeted-MBs were injected systemically in mice bearing MDA-MB-231 tumors (Grp 1) and compared with two control groups: Ad-loaded, non-targeted MBs (Grp 2) and free Ad (Grp 3) administered under the same conditions. Two days after administration the blood levels of secreted embryonic alkaline phosphatase (SEAP) reporter in Grp 1 mice (16.1 ng ml --1 ± 2.5) were significantly higher (Po0.05) than those in Grp 2 (9.75 ng ml --1 ± 1.5) or Grp 3 (4.26 ng ml --1 ± 2.5) animals. The targeted Ad delivery was also confirmed by fluorescence imaging. Thus, Ad delivery by targeted MBs holds potential as a safe and effective system for systemic Ad delivery for the purpose of cancer screening.
INTRODUCTION
Ultrasound (US) contrast agents, or microbubbles (MBs), are perfluorocarbon gas-filled lipid micelles with a size on the order of a micrometer. Their use during contrast-enhanced US has advanced a number of vascular imaging technologies, such as: vessel density characterization, 1 determination of microvascular flow rates 2 and evaluation of antiangiogenic therapy. 3, 4 In addition, the intrinsic stability and non-immunogenicity of MBs has led to their use in MB-based strategies for tumor delivery of therapeutic compounds, 5 plasmids 6 and viral vectors. 7 When exposed to an US pressure field, MBs physically resonate. Upon being systemically circulated and under certain US exposure conditions, it has been shown that vibrating MBs can transiently improve vascular permeability and chemotherapeutic drug uptake. 8 Alterations in the malleable lipid exterior cause physical association of vectors with the MB surface resulting in augmentation of transgene expression during plasmid-based therapy. 9 Although targeting of these therapies has been limited to site-directed US, receptor targeting of MBs has been shown to further improve the efficacy of this drug delivery system. 10 Targeting MBs to receptors commonly overexpressed by a tissue of interest has been shown to improve contrast-enhanced US and overall MB accumulation at target sites. 11 The active targeting of MBs is achieved by conjugating receptor-specific ligands to the outer shell through either biotin--avidin chemistry or covalent linkage. 12 Ligand-modified MBs bind specifically to molecular targets providing enhanced visualization during contrast-enhanced US through localized MB accumulation, while unbound MBs are cleared from the circulation. 13 Improved MB aggregation using targeted strategies has been demonstrated in the molecular imaging of inflammation, 14--16 intravascular thrombi 17, 18 and tumor angiogenesis. 19--21 MB targets have evolved from single to multiple receptor moieties with well-characterized synergistic benefits of multi-target strategies. 22--24 In the current study, MBs were targeted to a V b 3 integrins, P-selectin and vascular endothelial growth factor receptor-2 (VEGFR2) in order to improve MB accumulation in tumor vasculature and payload delivery. Targeting of these receptors in combination using a triple-targeted strategy has been shown to improve MB accumulation in tumor vasculature over single-and dual-targeted moieties. 25 Various MB-based approaches have been explored to improve cancer therapy. One strategy of US-mediated drug delivery involves a combination of MBs, US and a therapeutic compound without physical association of the latter with MBs. 26 In this instance, an augmented delivery is achieved through US-mediated MB destruction. Other mechanisms of US-assisted payload delivery involve physical association between MBs and a therapeutic compound. 6, 27 One of those involves labeling compounds, such as hydrophilic pDNA attached to the exterior of protein-shelled MBs by non-covalent interactions. 28 Other strategies have capitalized on the unique structure of the MB lipid shell to enable its association with lipophilic compounds, such as paclitaxel, through physical incorporation into the MB core. 29, 30 Additional approaches involve double-emulsified MBs that physically encapsulate hydrophilic macromolecules such as pDNA 31 or doxorubicin. 32 In the latter studies, complete encapsulation of the payload compound was proven beneficial for systemic delivery, considering that the compound was shielded from immune response and nonspecific sequestering mechanisms, while the MB shell remained innocuous. Recently, a novel method of MB packaging was demonstrated where adenovirus (Ad) particles were encapsulated by reconstituting lyophilized MBs with a concentrated Ad solution in the presence of perfluorocarbon gas. 33 When the freeze-dried MBs were reconstituted, the lipid shell encapsulated the concentrated Ad particles present in the solution, effectively loading intact particles. Human complement was then used to inactivate nonloaded Ad particles. This approach of MB packaging was further evaluated using a therapeutic Ad in a pre-clinical study. 34 The success of breast cancer (BC) therapy shows a direct correlation with the stage and grade of the tumor at the time of diagnosis. 35 We recently constructed a diagnostic Ad agent, Ad5/ 3-Id1-SEAP-Id1-mCherry, with BC-specific induction of dual-reporter expression: a secreted embryonic alkaline phosphatase (SEAP) enzyme for blood-based cancer screening and a fluorescent reporter mCherry for localized tumor imaging. 36 The tumorspecific promoter Id1, driving expression of each reporter in the above diagnostic Ad, possesses a cancer-selective (tumor-on, liveroff) activation profile with its transcriptional activity directly correlating with the aggressiveness of cancer phenotype. 37 To achieve augmented infectivity and detection sensitivity for BC, the Ad was genetically modified to encode a human Ad serotype chimera (Ad5/3) fiber, altering viral tropism to Ad3 receptor(s) 38 and thereby circumventing deficiency of the native coxsackie-andAd receptor, commonly downregulated in cancer cells. 39 This diagnostic Ad agent has earlier demonstrated sensitivity for BC detection. 36 Clinical applicability of cancer therapy involving MB packaging and tumor targeting has been limited by the site-directed nature of the US-triggered MB payload release mechanism, which has utility only when the exact location of malignancy is known. The mechanism of MB payload release in cancer screening applications must, therefore, be independent of site-directed US induction. The systemic half-life of MBs (on the order of minutes) in circulation is limited by their nonspecific disruption from pulmonary capillary passage, turbulent flow pressure and hydrostatic forces. 6 When a MB ruptures under hydrostatic pressure, the perfluorocarbon gas diffuses out, while the lipid cortex begins to bleb. It is hypothesized that during this blebbing process, the payload containment fails and loaded compounds are released. 27 Therefore, when the loaded MB is bound to the target site its molecular content can be naturally released over time without need for the triggering step. This payload delivery method combined with the shielding factor of MB packaging make this approach a viable alternative to direct systemic administration of free vectors.
In this study, we explored a novel strategy of MB-mediated payload delivery to the tumor vasculature for the BC screening application. The benefits of payload encapsulation by MBs include the shielding from the natural Ad-sequestration/neutralization mechanisms that present a major challenge for the effective systemic Ad delivery. In addition, the payload encapsulation protects the patient from immunogenic complications associated with traditional therapy. These benefits may allow lowering the therapeutic dose and extending pharmacological half-life of targeted therapeutics leading to improved treatment safety.
In this report, the dual-reporter Ad was loaded in MBs, using the lyophilized reconstitution method, and targeted to tumor vasculature via three distinct receptors a V b 3 , P-selectin and VEGFR2 simultaneously. After systemic administration and subsequent binding of the targeted MBs to tumor vasculature, the payload was spontaneously released as a result of MB dissipation leading to Ad infection of the neighboring cancer cells. Following the Ad cell infection the cancer-specific activation of both Id1 promoters induced expression of a fluorescent reporter mCherry and tumor-secreted enzyme SEAP, which enabled a localized tumor imaging and blood-based BC detection, respectively.
MATERIALS AND METHODS

Culture methods and in vitro experiments
MDA-MB-231 human BC and mouse angiosarcoma SVR (SVEN 1 RAS) endothelial cell lines were obtained from the American Tissue Type Collection (Manassas, VA). The MDA-MB-231 cell line was maintained in Dulbecco's modified Eagle's medium, 10% fetal bovine serum and 1% Lglutamine. The mouse SVR cell line was maintained in Dulbecco's modified Eagle's medium, 5% fetal bovine serum and 1% L-glutamine. All cells were cultured to 70--90% confluence before passaging. Cell lines were grown at 37 1C and 5% CO 2 . Cell numbers were determined with hemocytometer and Trypan blue dye exclusion.
MB loading and targeting
Ad loading was performed using custom lyophilized, biotin-coated MBs (Targestar-B, Targeson, San Diego, CA). Vials (3 Â 10 8 MB/vial, average MB size distribution 1.52 mm each) were reconstituted with a 0.7 ml (7 Â 10 10 plaque forming unit (PFU)) solution of replication-incompetent Ad5/3-Id1-SEAP-Id1-mCherry, 36 Ad5/3-CMV-luc 40 or Ad5/3wt-pIXmRFP1 with the capsid protein IX (pIX)-fused mRFP1.
41 Ad-loaded MBs were then treated with 10 Â volume human complement sera (60 mg ml --1 , S1764, SigmaAldrich, St Louis, MO) followed by 30-min incubation at room temperature. Ad-loaded MBs were then washed by 3 Â centrifugation (400 g for 3 min) with 10 Â volume phosphate-buffered saline (PBS) to remove unloaded particles. Infranatant from the final wash was used for background (control) measurements. Following washes, MBs were conjugated in a triple-targeted motif using biotinylated, rat immunoglobulin G antibodies against mouse a V b 3 (13-0512, ebioscience, San Diego, CA), mouse Pselectin (553743, BD Pharmingen, San Diego, CA) and mouse VEGFR2 (13-5821, ebioscience) according to the manufacturer's protocol. Briefly, biotincoated MBs were incubated with streptavidin followed by PBS centrifuge wash. MBs were then incubated with biotin-conjugated antibodies (13.3 mg each) for 20 min followed by 3 Â centrifuge washing to remove excess antibody. Following each conjugation, MB concentration was determined by hemocytometer.
In vitro experiments
All in vitro experiments were conducted in triplicates. Cells were plated 24 h before Ad infection. Experimental multiplicity of infection ratios were calculated based on PFU titers determined by a standard agarose-overlay plaque assay. Background values for the SEAP expression analysis were obtained from culture media collected in parallel from uninfected cells at the corresponding time points. A total of five in vitro experiments were performed: Figure 1a Ad5/3-CMV-Luc was aliquoted (4.4 Â 10 8 PFU per tube in 0.1 ml) while a 1 : 2 serial dilution of human complement sera (60 mg ml --1 ) was prepared in 0.4 ml PBS with dilutions ranging from 15 to 0.218 mg and sequentially added to Ad tubes. Ad solutions containing complement were then incubated 30 min at room temperature or 37 1C. After incubation, Ad solutions containing serial dilution of human complement were added to adherent MDA-MB-231 BC cells (1 Â 10 6 cells per well) and incubated for 30 min at 37 1C. Cells were then washed 3 Â with PBS followed by addition of a complete medium. After 24 h, luciferin substrate (Caliper Life Sciences, Mountain View, CA) was added (15 mg per well) and plates were imaged for 60 s at the binning of 8 with an IVIS-100 CCD imaging system (Caliper Life Sciences). Matched region of interest analysis was performed using instrument software (Living Image 3.2, Caliper Life Sciences) to quantify mean luciferase (Luc) counts per well. In Figure 1b , three vials of lyophilized, biotin-coated MBs were reconstituted with 7 Â 10 10 , 3.5 Â 10 10 or 1.75 Â 10 10 PFU of Ad5/3-Id1-SEAP-Id1-mCherry followed by complement inactivation. Three additional vials were prepared in parallel without complement inactivation. Following 3 Â centrifuge wash of all vials, Ad-loaded MBs were aliquoted into tubes (1 Â 10 6 MB per tube) followed by the addition of a monoclonal mouse antibody against the Ad5 hexon (LF-MA0177, Thermo-Scientific, Rockford, IL).
A phycoerythrin (PE)-conjugated anti-mouse immunoglobulin G (1030-09, Southernbiotech, Birmingham, AL) was used as a secondary antibody. Ad-loaded MB groups were analyzed for fluorescent counts (10k event minimum) using an Accuri C6 flow cytometer (Accuri Cytometers, Ann Arbor, MI). Tubes with MBs and secondary antibody (immunoglobulin G) alone were used to establish background. In Figures 1c and d , lyophilized, biotin-coated MBs were reconstituted with Ad5/3wt-pIXmRFP1 followed by 3 Â PBS washes to remove free particles. Ad-loaded MBs were then applied dropwise to microscope slides and a glass cover slip was added. Ad-loaded MBs were imaged for RFP1 fluorescence using a solid state red laser mounted on a Leica SP2 confocal laser-scanning microscope (Leica Microsystems, Bannockburn, IL) at 63 Â oil immersion objective. PBS reconstituted MBs mixed with Ad5/3wt-pIXmRFP1 were used as control. In Figure 2 , MDA-MB-231 cells (3.5 Â 10 5 cells per well) were plated in 24 black-well plates and incubated overnight to allow adherence. Ad-loaded MBs were prepared with Ad5/3-CMV-Luc followed by complement inactivation. After the final wash, the infranatant was added to the wells in equal volumes as the Ad5/3-CMV-Luc loaded MB addition. Ad-loaded MBs (6.15 Â 10 7 in 0.1 ml) were added to adherent MDA-MB-231 cells. Subsequently, 0.1 ml of the final wash infranatant was added to separate wells. Free Ad5/3-CMV-Luc was then added to separate wells in a 1 : 2 titration beginning at 1.3 Â 10 9 PFU and ending at 1.3 Â 10 6 PFU to serve as an Ad infectivity standard. Plates were then incubated overnight at 37 1C. At 24 h after infection, luciferin substrate was added (15 mg per well) and plates were imaged for 60 s at a binning of 8 with an IVIS-100 CCD imaging system. Matched region of interest analysis was performed to quantify mean Luc counts per well. In Figure 3 , triple-targeted, Ad5/3-Id1-SEAP-Id1-mCherry loaded MBs were generated and complement inactivated. Ad-loaded targeted MBs (1.7 Â 10 6 MBs per well) were then added in triplicate to wells in six-well plates containing 1 : 1 co-cultured mouse SVR and MDA-MB-231 cells (plated 24 h prior, 2.5 Â 10 5 cells per well). Mouse SVR cells express the mouse a V b 3 , P-selectin and VEGFR2 receptors required for targeted MB binding. 25 MDA-MB-231 cells express the human Ad5/3 receptor and Id1 cancer promoter. 36 Ad-loaded non-targeted MBs (1.7 Â 10 6 ) and free Ad particles (8.5 Â 10 6 PFU, multiplicity of infection ¼ 21) were prepared using the same protocol and served as controls. Treated wells were incubated while rocking for 30 min at room temperature. After incubation, plates were washed 3 Â with PBS. After final wash, each well was viewed at 40 Â with an Olympus IX70 microscope (Olympus America, Melville, NY) followed by complete media addition (Dulbecco's modified Eagle's medium, 7.5% fetal bovine serum and 1% L-glutamine) and placed in incubator for 24 h. Media from all wells was then removed and screened for SEAP. Wells were also imaged for mCherry fluorescence (see fluorescence imaging methods).
In vivo evaluation
Athymic female nude mice were obtained from Frederick Cancer Research (Frederick, MD) and implanted with 4 Â 10 6 (0.1 ml) MDA-MB-231 cells in the mammary fat pad. Four weeks after implant, mice were sorted into three groups (n ¼ 5) based on tumor size (average tumor size: 271.3 ± 72 mm 3 ). Targeted, Ad5/3-Id1-SEAP-Id1-mCherry loaded MBs (complement-inactivated) were prepared and intravenously injected (tail vein) into five mice at 1 Â 10 7 MBs per mouse in 0.1 ml dose (0.05 ml MBs þ 0.05 ml saline). Subsequently, non-targeted Ad5/3-Id1-SEAP-Id1-mCherry loaded MBs (complement-inactivated) were prepared and intravenously injected (1 Â 10 7 MBs per mouse) into a separate mouse group. The final group received free Ad5/3-Id1-SEAP-Id1-mCherry (5 Â 10 7 PFU per mouse in 0.05 ml) without complement inactivation. Simultaneously, this control group received non-targeted, unloaded MBs (1 Â 10 7
MBs per mouse in 0.05 ml), which were reconstituted with PBS. A background control group was then prepared with five non-tumor-bearing mice that received targeted, Ad5/3-Id1-SEAP-Id1-mCherry loaded MBs (1 Â 10 7 MBs per mouse in 0.1 ml dose). Blood was then collected on days 1, 2 and 4 post-injection from anesthetized mice by retro-orbital collection with heparin-treated capillary tubes. Collections were then spun and blood plasma was obtained for SEAP analysis. After day 4, mice were killed and tumors were excised and imaged for mCherry fluorescence. Institutional Animal Care and Use Committee at the University of Alabama at Birmingham approved all animal procedures.
SEAP analysis
Blood-based reporter analysis was conducted using a Great EscAPe Fluorescence Detection Kit (Clontech, Mountain View, CA, USA). All steps were performed according to the established protocol (New Fluorescent Great EscAPE SEAP Assay (January 1997) CLONTECHniques XII (1): 18--19).
Fluorescence imaging
In vitro fluorescent images (20 Â ) were rendered using an mCherry 587 nm excitation/600 nm long pass filter on an inverted microscope with a halogen light source and Nuance multi-spectral camera. A liquid-crystal tunable wavelength filter in the camera was set for collection of emission images from 600 to 720 nm in 5 nm increments. Composite images (unmixed composites) were generated for each image cube by unmixing the spectral signature of the mCherry reporter proteins from those of background auto-fluorescence using a spectral library that was compiled from numerous spectral profiles collected from uninfected control cells under the same conditions. For tumor fluorescence images, mice were euthanized and tumors collected and imaged on day 4 post-injection with a Leica stereomicroscope (Model MZ-FLIII, Vashaw Scientific, Norcross, GA).
Statistical analysis
Statistical comparisons were performed using Minitab 15 statistical software (State College, PA). In Figure 1a , dose titration groups (15--0.437 mg) were compared with an analysis of variance test of mean Luc counts. An unpaired two-sample t-test was then used to compare mean Luc counts from the 0.437 mg dose versus the 0.218 mg dose group to determine the minimum amount of complement needed to inactivate Ad. In Figure 1b , an unpaired two-sample t-test was then used to compare PE counts from the 7 Â 10 10 PFU MB group and both the 3.5 Â 10 10 and 1.75 Â 10 10 PFU MB groups. In addition, an analysis of variance test of PE counts was performed on all complement-inactivated MB groups. In Figure 2a , mean Luc counts from the Ad-loaded MB treated group were compared with mean Luc counts from the infranatant-treated group using an unpaired two-sample t-test. For Figure 3c , an unpaired two-sample t-test was used to compare SEAP amounts from the Ad-loaded targeted MB group versus the Ad-loaded non-targeted MB group. The test was repeated to determine the significant difference between the SEAP amounts from the free Ad and the Ad-loaded targeted MB groups. For the in vivo analysis, an unpaired two-sample t-test was performed to determine significance of background-subtracted SEAP amounts between the Ad-loaded targeted MB groups and both the Ad-loaded non-targeted MB and free Ad groups. A P-value of o0.05 was considered statistically significant.
RESULTS
Complement inactivation of Ad
Systemically administered Ad is known to undergo rapid sequestration from human circulation and functional inactivation by numerous factors including pre-existing anti-Ad antibody and the complement system. To determine the amount of human complement required for full inactivation of Ad particles, an in vitro complement inactivation assay was performed using a firefly Luc reporter-expressing E1-deleted vector (replication-incompetent) Ad5/3-CMV-Luc. The latter Ad (4.4 Â 10 8 PFU) was pre-incubated with various amounts of human complement ranging from 15 to 0.218 mg either at room temperature or 37 1C before in vitro infection of MDA-MB-231 BC cells. At 24 h after infection, bioluminescent imaging of the above cell culture was used to quantify Luc expression that was proportional to the residual Ad infectivity, shown in Figure 1a . Although no significant change (P40.05) in Ad inactivation efficiency was observed between samples receiving from 15 to 0.437 mg of complement, dilutions containing 0.218 mg of complement showed a significant decrease in Ad inactivation (Po0.05), suggesting that 1 mg of human complement is sufficient to fully inactivate 1 Â 10 9 PFU of the Ad vector. The experiments also showed that the 0.218 mg dose was sufficient to reduce the Ad transduction efficiency 3-fold relative to the complement-untreated Ad (Figure 1a ). Of note, no significant difference in Ad inactivation rates was observed between the room temp and the 37 1C incubation conditions (P40.05).
Anti-Ad antibody binding of complement-inactivated Ad-loaded MBs Susceptibility of the Ad-loaded MBs to neutralization with preexisting anti-Ad antibodies is a critical biological issue and an important step in the biological evaluation of the MB-based Ad delivery systems. To assess the ability of an Ad-specific antibody to bind (and potentially neutralize), the Ad-loaded MBs, an antibodybinding assay was performed by probing the Ad-loaded MBs with a monoclonal antibody against the Ad5 capsid protein hexon. To this end MBs were reconstituted in the presence of 7 Â 10 10 , 3.5 Â 10 10 or 1.75 Â 10 10 PFUs of the Ad5/3-Id1-SEAP-Id1-mCherry BC-detection vector, followed by in vitro Ad inactivation with human complement. The Ad-loaded MBs were then evaluated for binding to the Ad5 capsid (hexon)-specific primary antibody and a PE-conjugated secondary antibody by flow cytometry technique. In parallel, the same PFU-reconstitution MB groups were evaluated for the efficiency of PE/antibody labeling without prior complement inactivation of the MBs. The efficiency of Ad5-specific antibody binding to the complement-inactivated MB groups was on average 18-fold lower than to the complement-untreated MB groups (Figure 1b) . In the absence of complement inactivation, the mean fluorescent counts (MFCs) for the 7 Â The results of this experiment confirm complete Ad loading in the MB core. In addition, the results suggest that partial encapsulation of the vector takes place during MB lyophilized reconstitution with some Ad particles exposed to the surface by association with the lipid layer. Accessibility of the MB surfaceassociated Ad particles for interaction with human complement is evidenced by the dramatic (18-fold) loss in anti-Ad antibody binding following complement treatment. This result indirectly suggests that MB-shielding of the fully encapsulated Ad particles is likely to also prevent systemic immunogenicity. Thus, following complement inactivation of the MB surface-exposed (partially encapsulated) Ad particles the loaded MBs could become invisible to (non-reactive with) pre-existing anti-Ad5 antibodies commonly present in patient's serum.
Visualization of the Ad-loaded MB To confirm feasibility of Ad encapsulation into the targeted MBs by the lyophilized reconstitution method, we used fluorescently labeled particles of a unique Ad5/3wt-pIXmRFP1 virus with mRFP1-tagged capsids 41 to allow a direct visualization of MB Adloading by confocal fluorescent microscopy. The MB core localization of the mRFP1-labeled particles, evidenced by a representative composite (merged) image (Figure 1c ), suggests capability of MBs to fully encapsulate Ad particles. In contrast, PBS-reconstituted nonloaded MBs mixed with Ad5/3wt-pIXmRFP1 were negative for corelocalized fluorescence (Figure 1d In vitro analysis of Ad-loaded targeted MBs To evaluate the potential of the MB-based Ad delivery system for systemic detection of BC, we utilized a previously reported Ad5/3-Id1-SEAP-Id1-mCherry BC diagnostic vector in the context of MBs triple-targeted to mouse endothelial cells. The Ad-loaded targeted MBs were added to co-cultured mouse SVR and human BC cells.
The mixed cell population enabled evaluation of MB targeting selectivity for the target receptor-expressing mouse endothelial cells. Treatment of co-cultured cells with the Ad-loaded targeted MB preparations resulted in localized clustering of the targeted MBs around mouse SVR cells expressing a V b 3 , P-selectin and VEGFR2 receptor targets (Figure 3a) . No MB clustering around cells was observed when Ad-loaded non-targeted MBs were used instead (Figure 3b) . Binding of the Ad-loaded targeted MBs to the cell monolayer was also evidenced by the SEAP detection assay results: the levels of the SEAP reporter expression were significantly greater for the Ad-loaded targeted MB group (7.1 Â 10 2 ng ml --1 ±31.0) than for the non-targeted MB group (4.6 Â 10 2 ng ml --1 ± 48.7) (Po0.01). On the contrary, there was no significant difference between the free (7.7 Â 10 2 ng ml --1 ± 63.1) and the Ad-loaded targeted MB group (7.1 Â 10 2 ng ml --1 ±31.0) (P40.05), demonstrating an enhanced in vitro performance of the complement-inactivated targeted MBs in protecting Ad particles and endothelial cell targeting. The pattern of SEAP reporter expression was validated by mCherry fluorescence expression in human MDA-MB-231 cells because of the human-specific Ad induction of this fluorescent reporter expression for the free Ad (Figure 3d ), Ad-loaded MBs (Figure 3e ) and the Ad-loaded targeted MB experimental groups (Figure 3f ).
In vivo analysis of Ad-loaded targeted MBs MDA-MB-231 tumor-bearing mouse groups (n ¼ 5) were prepared and IV injected with free Ad5/3-Id1-SEAP-Id1-mCherry, Ad-loaded MBs or Ad-loaded targeted MBs. Figure 4a compares SEAP levels obtained from the above groups on days 1, 2 and 4. The shown SEAP concentrations were calculated by subtracting the background SEAP concentrations measured in non-tumor-bearing mice (n ¼ 5) that received Ad-loaded targeted MB. The SEAP levels from Ad-loaded targeted MB group on day 2 (16.1 ng ml --1 ±2.5) were significantly greater than those from the Ad-loaded MB group (9.75 ng ml±1.5) or free Ad group (4.26 ng ml --1 ±2.5) (Po0.05) (Figure 4a ). However, there was no significant difference between the Ad-loaded MB (non-targeted) and the free Ad groups (P40.05). A representative overlay (composite) image of sliced BC tumor xenografts isolated from a mouse of the Ad-loaded targeted MB group on day 4 after injection, showed the strongest tumor-localized mCherry fluorescence (Figure 4d ) relative to tumors from the other groups (Figures 4b and c) . This result showed an advantage of MB targeting to tumor vasculature as well as presents proof-of-principle for the MB-based systemic delivery of Ad vectors with the purpose of cancer detection.
DISCUSSION
Described here is a strategy for systemic delivery of Ad vectors for the specific purpose of BC detection. The diagnostic, dual-reporter Ad, Ad5/3-Id1-SEAP-Id1-mCherry, was loaded in MBs, which were targeted to endothelial receptors overexpressed on the tumor vasculature. Using a fluorescently tagged Ad as a diagnostic vector analog, Ad-loaded MBs were imaged using fluorescent confocal microscopy to confirm complete packaging, that is, enclosure of the fluorescent Ad within the MB core. In order to assess the full potential of the Ad-loaded MBs and remove residual unloaded Ad particles, human complement was used to bind to and inactivate unloaded particles. To evaluate the potential susceptibility of the MB delivery system to pre-existing anti-Ad antibody binding in circulation, Ad-loaded MBs were probed with a monoclonal antibody against the Ad5 capsid protein hexon. For this experiment, complement inactivation was shown to reduce antibody binding 18-fold over untreated groups, demonstrating the reduced immunoreactivity of the complement-inactivated MBs. In addition, the number of functional Ad particles loaded within each MB was determined using a Luc reporter expressing Ad and was found to be 4.7±0.2 PFU per MB. In vitro analysis of the Ad-loaded targeted MBs was performed using co-cultured mouse endothelial (SVR) and human BC (MDA-MB 231) cells. The Ad-loaded targeted MBs were shown to cluster around the endothelial cells, while non-targeted MBs failed to adhere to cells and were removed during wash steps. Complement-inactivated Ad-loaded targeted MBs were shown to express SEAP and mCherry reporters at the levels equivalent to those of the unloaded (free) Ad in co-cultured cells. In vivo experiments using MDA-MB-231 tumor-bearing mice demonstrated the benefit of targeted MBs in systemic delivery Ad to tumor with SEAP levels being significantly greater than both the Ad-loaded non-targeted MBs and the free Ad receiving experimental groups (Po0.05). Non tumor-bearing control mice injected with Ad-loaded targeted MBs provided the reporter background levels for each time point measured. A detectable expression of the reporters within 24--48 h after virus administration was consistent with our previous studies using this dual-reporter system. 36 The enhanced tumor delivery afforded by the Ad-loaded targeted MBs was additionally evidenced by in vivo imaging of the fluorescent reporter expression in tumors.
Confocal fluorescence imaging of MBs reconstituted with mCherry-labeled Ad particles demonstrated localization of the mCherry fluorescence to the gas-filled, hydrophobic core of MBs. This result was counter-intuitive, considering that Ad particles are hydrophilic. It is hypothesized that during the lyophilized MB reconstitution, the high concentration of Ad in solution prompts uptake of droplets of Ad solution along with an ambient perfluorocarbon gas within the lipid micelle. The hydrophilic solution is repelled from the hydrophobic lipid tails and localized to the inner core forming hydrophilic micelles. The fluorescent structures inside the MB core visualized in our experiment are likely to represent those micelles of Ad solution. Once the Adloaded MB is in circulation, the natural blebbing that occurs as MB containment fails, releasing the captive Ad micelles, formerly held within in the core by hydrophobic interactions.
To estimate the number of infectious Ad particles fully loaded within an average-size MB, a concentrated solution (1 Â 10 11 PFU ml --1 ) of non-replicative Ad5/3-CMV-Luc virus was used to reconstitute a lyophilized vial containing 3 Â 10 8 MBs. The background-subtracted Luc expression readings produced by MDA-MB-231 BC cells, treated with the Ad-loaded MBs were matched with Luc counts generated from a free Ad5/3-CMV-Luc infectivity standard. Using this strategy, it was found that a single MB can on average encapsulate 4.7 ± 0.2 functional equivalents (PFUs) of Ad particles. Quantifying the level of Luc expression on the Ad-loaded MB-treated cells allowed calculating the total number of functional Ad particles, excluding non-infectious and/ or complement-inactivated ones. During MB preparation, the integrity of the Ad particles may have been compromised, leading to a loss of infectivity. An alternative method to quantify the total number of Ad particles loaded within the MBs would involve quantification of total Ad DNA encapsulated by the reconstituted Ad-loaded MBs. However, this approach would simply reveal the total number of loaded Ad particles: both functional and nonfunctional. Thus, quantification of fully infectious Ad particles per MB was essential for subsequent determining the equivalent amount of the same Ad needed for treatment of the control groups. The determined value (4.7 ± 0.2 PFU per MB) was used to assure equal dosing of unloaded and loaded Ad particles. A possible limitation of the MB loading method is the titerdependent MB loading. It is hypothesized that a greater Ad titer may increase the PFU/MB ratio thereby improving the overall performance of the Ad-loaded MBs. In addition, a larger MB size distribution may permit a greater uptake of intact Ad particles.
MBs with a perfluorocarbon gas interior improve MB stability in an aqueous environment. 6 The longer MB half-life enables the US contrast agent to remain in circulation and maintain the bubble echogenicity required for contrast-enhanced US. Previously investigated methods for drug or vector delivery using MBs rely on the natural effect of MB destruction during high frequency US to nonspecifically deliver a payload to the site of interest. For payload delivery applications independent of US, the improved stability of a perfluorocarbon MB adversely affects the delivery of loaded payload. In the absence of US, once the targeted MB is bound to the endothelium expressing the target receptors, the breakdown of the MB shell must occur to release the payload before the fastened MB is forced off because of the shear forces of circulation. In this regard, less stable MB would be beneficial for those applications where US triggering of payload release is technically unfeasible, particularly for generalized cancer detection applications. Future strategies of US-independent MB-based delivery may include less stable nitrogen or air-filled MB formulations, which may allow a more readily releasable payload.
This proof-of-principle study demonstrates the potential of targeted MB to deliver encapsulated Ad safely and more efficiently than traditional systemic delivery. Although the in vivo results are modest, they are significant, and will only be improved with future advancements in MB payload capacity and encapsulation techniques leading to greater Ad transduction efficiency. Future studies will include these advancements along with tissue biodistribution analysis, which would quantify liver uptake and circulatory persistence, and toxicity assays that would further quantify the improved patient safety afforded using encapsulated Ad.
Although this Ad delivery strategy is useful for cancer detection, the model can be extended to other applications where US-based payload release is not practical such as in atherosclerotic plaque detection or chemotherapeutic drug delivery for metastatic lesions. In addition, specific and nonspecific sequestering mechanisms, which normally reduce the compound's pharmacological half-life, would be circumvented using the MB delivery system. This would lead to a prolonged delivery of a compound or Ad, increasing the half-life and allowing lower doses to be administered. For example, inactivation of MB surface-associated Ad particles was shown to reduce anti-Ad5 hexon antibody binding, that is, the MB immunoreactivity. Elimination of these extraneous and detrimental particles would reduce first-line Ad sequestration by liver that normally hinders a systemic virus delivery.
Targeting Ad-loaded MBs to tissue for payload delivery without the requirement of external US triggering represents a novel use of MBs. The unique ability of MBs to package macromolecules and target systemic tissue makes them a viable alternative to traditional adenoviral therapy. Here, the MB was shown to fully encapsulate the Ad particles localizing them to the MB core where their immunoreactivity potential is the lowest. The enhanced tissue delivery and immunogenic protection afforded with MB loading permits reduced payload dosage, potentially reducing its clinical toxicity for the patients and thereby circumventing the complications traditionally associated with gene therapy. 42 The safety of MBs for systemic application has been well documented 43 and the Food and Drug Administration approval for human use further augments the auspicious potential for immediate clinical use.
